| Original language | English (US) |
|---|---|
| Pages (from-to) | 2974-2978 |
| Number of pages | 5 |
| Journal | Leukemia |
| Volume | 33 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2019 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. / Mascarenhas, J.; Kosiorek, H.; Prchal, J.; Yacoub, A.; Berenzon, D.; Baer, M. R.; Ritchie, E.; Silver, R. T.; Kessler, C.; Winton, E.; Finazzi, M. C.; Rambaldi, A.; Vannucchi, A. M.; Leibowitz, D.; Rondelli, D.; Arcasoy, M. O.; Catchatourian, R.; Vadakara, J.; Rosti, V.; Hexner, E.; Kremyanskaya, M.; Sandy, L.; Tripodi, J.; Najfeld, V.; Farnoud, N.; Salama, M. E.; Weinberg, R. S.; Rampal, R.; Goldberg, J. D.; Mesa, R.; Dueck, A. C.; Hoffman, R.
In: Leukemia, Vol. 33, No. 12, 01.12.2019, p. 2974-2978.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
AU - Mascarenhas, J.
AU - Kosiorek, H.
AU - Prchal, J.
AU - Yacoub, A.
AU - Berenzon, D.
AU - Baer, M. R.
AU - Ritchie, E.
AU - Silver, R. T.
AU - Kessler, C.
AU - Winton, E.
AU - Finazzi, M. C.
AU - Rambaldi, A.
AU - Vannucchi, A. M.
AU - Leibowitz, D.
AU - Rondelli, D.
AU - Arcasoy, M. O.
AU - Catchatourian, R.
AU - Vadakara, J.
AU - Rosti, V.
AU - Hexner, E.
AU - Kremyanskaya, M.
AU - Sandy, L.
AU - Tripodi, J.
AU - Najfeld, V.
AU - Farnoud, N.
AU - Salama, M. E.
AU - Weinberg, R. S.
AU - Rampal, R.
AU - Goldberg, J. D.
AU - Mesa, R.
AU - Dueck, A. C.
AU - Hoffman, R.
N1 - Funding Information: This study was an investigator-initiated phase 2 clinical trial that was performed in compliance with an Investigational New Drug Application and approved by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai and at all participating sites. It was supported by the National Cancer Institute, and PEG was generously supplied by Roche/Genentech. Funding Information: Conflict of interest J.M. reports clinical trial research support paid to the institution from Incyte, Roche, Novartis, CTI Biopharma, Janssen, Merck, Promedior, and Celgene; clinical trial steering committee and scientific advisory board member: Roche, CTI Biopharma, Incyte, and Celgene. M.R.B. reports clinical trial research support paid to the institution from Abbvie, AI, Astellas, Forma, Incyte, Kite, and Takeda. M.A. reports research grant support paid to institution from Incyte, CTI Biopharma, Samus Therapeutics, Janssen, and Gilead. R.T.S. Funding Information: Acknowledgements This research was made possible by a grant from the National Cancer Institute of the National Institute of Health (MPN Research Consortium Grant, 5P01CA108671–09) and generous independent, unrestricted support from Roche Genentech.
PY - 2019/12/1
Y1 - 2019/12/1
UR - http://www.scopus.com/inward/record.url?scp=85069946674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069946674&partnerID=8YFLogxK
U2 - 10.1038/s41375-019-0524-7
DO - 10.1038/s41375-019-0524-7
M3 - Letter
C2 - 31363161
AN - SCOPUS:85069946674
VL - 33
SP - 2974
EP - 2978
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 12
ER -